Clinical Trial Update: Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies [Phase 3]

View source ↗

Summary

Open-label access for Berotralstat is being offered to hereditary angioedema patients who were previously enrolled in Berotralstat studies, within a Phase 3 pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Berotralstat (berotralstat)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Hereditary Angioedema, HAE | Phase 3 | Status: ENROLLING_BY_INVITATION